Neuralink Stock: Price, IPO Odds, and How to Invest in 2026

Investing // Updated: September 11, 2026 // 12 min read // Lindsey A. Kennedy, Senior Technical Writer

There is no Neuralink stock ticker on any public exchange. Neuralink Corporation is a private company. Its shares do not trade on the NYSE, Nasdaq, or any registered exchange accessible to retail investors. The most recent private market valuation — based on Neuralink's $650 million Series E funding round in June 2025 — values the company at approximately $9.65 billion. As of August 25, 2026, Nasdaq Private Market estimates the per-share price at $240.03, based on secondary market activity and proprietary data. No IPO date has been announced. No SEC filing exists. Neuralink's Elon Musk has given no timeline for going public.

Contents

• There Is No Neuralink Stock — Here's What Exists
• Neuralink at a Glance (September 2026)
• What Neuralink Does: Products, Technology, and Patients
• Clinical Trial Results in 2026: The Real Numbers
• Neuralink's Product Roadmap: Telepathy Gen 2, Blindsight, VOICE
• Neuralink Valuation and Funding History
• Neuralink IPO: Will It Ever Go Public?
• How to Invest in Neuralink in 2026: 5 Real Options
• Brain-Computer Interface Stocks: The Competitive Landscape
• 5 Risks Before You Invest in Neuralink
• FAQ
• Summary

There Is No Neuralink Stock — Here's What Exists

Neuralink Corporation (also styled Neuralink Corp.) has never filed a Form S-1, never listed on any exchange, and has never been assigned an official stock ticker by a regulated market. What you see labeled 'NEUR.PVT' on some finance platforms — including Yahoo Finance — is a tracking label for a private company, not a publicly traded security. The '.PVT' suffix is the tell: PVT means private.

Forge Global — one of the largest private market trading platforms and a subsidiary of Charles Schwab — confirms: 'Neuralink does not have a public stock price because it is a privately held company. There is currently no ticker symbol for Neuralink stock.' Forge and similar platforms (Nasdaq Private Market, Notice, UpMarket) facilitate secondary transactions between existing private shareholders — employees, early investors, angel investors — and new accredited buyers. These are not public market trades.

Neuralink at a Glance (September 2026)

What Neuralink Does: Products, Technology, and Patients

Neuralink develops implantable brain-computer interfaces (BCIs) — devices that sit inside the skull and read electrical signals directly from neurons. The core hardware is the N1 chip: roughly the size of a US quarter (23 mm across, 8 mm thick), implanted in the motor cortex by the company's R1 surgical robot. The N1 carries 128 ultra-thin threads with more than 1,000 electrodes — each thread thinner than a human hair — that record the electrical patterns produced when neurons fire.

The system decodes those patterns using machine learning. When a paralyzed person intends to move their hand — even though the physical movement doesn't happen — the motor cortex still produces the corresponding neural activity. Neuralink's algorithms translate that activity into digital commands in real time: cursor movements, wheelchair steering, robotic arm control.

Neuralink's first product, branded Telepathy, was implanted in the first human clinical trial participant — Noland Arbaugh, paralyzed from the shoulders down after a 2016 diving accident — on January 28, 2024. Arbaugh quickly surpassed the world record for cursor control speed using only his thoughts. As of 2026, Neuralink's PRIME clinical trial has enrolled 26 patients globally.

Clinical Trial Results in 2026: The Real Numbers

Neuralink published its two-year clinical results summary in early 2026, covering the PRIME study from January 2024 through January 2026. The headline numbers: multiple participants achieved neural decoding speeds of over 10 bits per second — matching or exceeding the average mouse control rate for non-impaired users. The company reports no serious adverse events related to the device.

Neuralink's Product Roadmap: Telepathy Gen 2, Blindsight, VOICE

Telepathy Gen 2 — 3× Capability

On January 28, 2026 — the two-year anniversary of the first human implant — Musk announced that the next-generation Neuralink device would offer 3× the capability of the current N1, with a target availability date of late 2026, pending regulatory review. Internally, Neuralink has been testing versions with 3,000 electrodes (up from 1,000 on the current implant), along with mechanical improvements to reduce the thread displacement issues seen in the first cohort.

Blindsight — Vision Restoration

Blindsight is Neuralink's second implantable device, targeting the visual cortex rather than the motor cortex. It received FDA Breakthrough Device Designation in September 2024 — a regulatory pathway that accelerates review for potentially life-changing medical devices. Musk has described the initial experience as 'Atari resolution' that improves over time as the brain adapts to the new input.

Blindsight is designed for people who are completely blind — including those who have lost both eyes and their optic nerve, as long as the visual cortex is intact. In August 2026, Musk stated that Neuralink expects to perform its first Blindsight implant in a human within 6–12 months. However, this human trial hasn't started yet as of September 2026 — animal testing continues.

VOICE — Real-Time Speech Restoration

VOICE is a clinical trial targeting people who have lost the ability to speak due to ALS, stroke, or other conditions. Rather than decoding motor intent (movement), VOICE reads signals from the brain areas associated with speech production. Neuralink has reported typing speeds of up to 40 words per minute via a 'virtual keyboard' model using decoded neural intent — a precursor to direct speech output.

Neuralink Valuation and Funding History

Neuralink has completed five known funding rounds. Here is the complete picture:

The gap between the official Series E valuation ($9.65B) and the secondary market high estimate ($35B per TechStackIPO) reflects the typical private market disconnect: early investors and employees may be marking their holdings at a premium above the last round on secondary platforms, anticipating future IPO price discovery. Neither figure represents a market-clearing price.

Nasdaq Private Market estimates the current per-share price at $240.03 (as of August 25, 2026) — based on a blend of secondary market activity, fund marks, and proprietary models. This implies a market cap somewhere between the official $9.65B and the higher secondary estimates. Notice.co's algorithmically-generated estimate is $295/share as of late August 2026 — suggesting the market is pricing in meaningful growth beyond the Series E terms.

Neuralink IPO: Will It Ever Go Public?

No IPO date has been announced. No Form S-1 has been filed with the SEC. No banker has been named. The only public statements about a potential Neuralink IPO are from Elon Musk himself — and they have all emphasized that it is not happening in the near term.

The key factors working against a near-term Neuralink IPO: Neuralink is still running investigational (pre-commercial) clinical trials. The Telepathy device has FDA clearance for human trials but not for commercial sale. Neuralink's own internal projections — cited in Chinese analyst reports from the Dongfang Securities 2026 BCI sector note — target FDA approval for Telepathy around 2029, with 2,000 annual procedures and approximately $100M in annual revenue. A company generating $0 commercial revenue is not a typical IPO candidate.

The June 2025 Series E raised $650M — providing Neuralink with 'substantial capital runway for continued clinical trials without immediate need for public market access', per TSG Invest's analysis. With $9.65B+ in private valuation and ample cash, Musk has no financial pressure to go public. The SpaceX precedent is instructive: SpaceX stayed private until June 2026 despite being valued above $1 trillion in secondary markets for more than two years.

How to Invest in Neuralink in 2026: 5 Real Options

Neuralink is not publicly traded. These are the legitimate paths to exposure, ranked from most direct to most indirect:

• ARK Venture Fund (ARKVX) — Most accessible for retail investors. Cathie Wood's ARK Invest led the Series E and holds Neuralink shares inside ARK Venture, a closed-end interval fund that accepts retail (non-accredited) investor subscriptions — unlike most private equity vehicles. Minimum investment requirements vary by broker. Neuralink is one of multiple private holdings; you're buying a fund, not Neuralink directly.
• Forge Global / Nasdaq Private Market — For accredited investors only. Forge (a Charles Schwab subsidiary) and Nasdaq Private Market facilitate secondary market transactions in Neuralink shares. These are real share transfers from existing holders (employees, angels) to new accredited buyers. Minimum investment is typically $50,000–$250,000+. Pricing is estimated from secondary activity.
• Tesla (TSLA) — Extremely indirect exposure. Neuralink and Tesla share Elon Musk as CEO and have discussed BCI integration with Optimus robots and Tesla vehicles. There is no financial relationship between Neuralink and Tesla — no cross-ownership, no supply agreement — but as the only Musk company currently publicly traded at scale, some investors use TSLA as a Musk-portfolio proxy. Google (Alphabet, GOOGL) also participated in early Neuralink rounds — providing fractional indirect exposure.
• BCI sector ETFs or public BCI stocks — Thematic exposure. There is no BCI-specific ETF as of September 2026. However, iShares Genomics Immunology and Healthcare ETF (IDNA) and ROBO Global Healthcare Technology and Innovation ETF (HTEC) include some BCI-adjacent holdings. For direct public BCI exposure, Synchron has reportedly been in acquisition discussions with multiple parties; Natus Medical (neuromonitoring) and Medtronic (which distributes some BCI products) offer adjacent exposure.
• Wait for a public offering. If Neuralink achieves commercial FDA approval around 2029 and files for an IPO, that would be the first opportunity for retail investors to buy shares at a market-clearing price. Sign up for IPO alerts via your brokerage and Nasdaq's IPO calendar. The risk: by the time a Neuralink IPO happens, the price will reflect years of additional growth already priced in.

Brain-Computer Interface Stocks: The Competitive Landscape

Neuralink has competitors across the BCI spectrum — invasive, non-invasive, and semi-invasive. Most are also private. Here's where the public (or public-adjacent) exposure exists:

5 Risks Before You Invest in Neuralink

• Zero commercial revenue — potentially for years. Neuralink generates no commercial revenue today. FDA approval for Telepathy is projected for approximately 2029. Any investment made now buys a clinical-stage medical device company with a multi-year timeline before the business can self-fund. Historical medical device company IPOs at this stage have frequently disappointed.
• Technical and safety risks. Thread migration was observed in the first patient (Noland Arbaugh), requiring algorithmic adjustment. The safety of long-term implants — over 10, 20, 30 years — is simply not known. Experts note that 'measuring success and safety will take time and disclosure of more information'. Previous Neuralink animal testing controversies (deaths of over 1,000 animals, disputed by Musk) remain in the public record.
• FDA regulatory complexity. Brain implants face the most stringent regulatory review in medical devices. FDA approval for Telepathy requires multi-year clinical trial completion, data analysis, and review. Any serious adverse event in the trial — regardless of causation — could delay or derail approval by years.
• Musk concentration risk. Musk is CEO of Neuralink, Tesla, SpaceX, X, The Boring Company, and now SpaceX AI. Neuralink may receive less management attention than it needs as these other companies scale rapidly. There is no named successor or independent operational CEO for Neuralink.
• Non-invasive competition may win. If Merge Labs (Sam Altman, OpenAI-backed, $850M, January 2026), Synchron, or other non-invasive BCI players can achieve comparable decoding performance without brain surgery, Neuralink's invasive approach may face a significant adoption barrier. Patients who can choose between 'open brain surgery' and 'ultrasound wearable' may overwhelmingly prefer the latter.

Neuralink Stock FAQ

Summary

Neuralink is one of the most watched private companies in the world — and still one of the hardest to invest in. The science is real: 26 patients enrolled, 10+ bits/second decoding, wheelchair control, digital art created with thought. The company is expanding from motor cortex to visual cortex to speech, with a next-generation 3× implant targeted for late 2026. The valuation has grown from $5B to $9.65B in two years, driven by actual patient results.

But Neuralink has no revenue, no IPO date, no commercial product, and no timeline that makes it accessible to retail investors today. The paths that exist — ARK Venture Fund, accredited secondary platforms, indirect sector exposure — are all imperfect proxies for a bet on a technology that may reshape medicine in the 2030s.

If you're serious about tracking this space, follow Neuralink's PRIME trial enrollment milestones, watch for the Telepathy Gen 2 regulatory filing, and monitor when Blindsight's first human trial begins. Those are the actual leading indicators — not social media posts or secondary market price estimates.

For coverage of other Musk ventures: SpaceX Stock (SPCX) 2026 Guide | Tesla Stock (TSLA) 2026 Guide | Starmind: SpaceX's Orbital AI Constellation. Full archive: optimusk.blog/blog.